GRIFOLS’ PLASMA DEARTH RECEDES (BUY; 28% UPSIDE)
20/10/21 -" Unlike the broader markets (i.e. STOXX600), Grifols (Buy, Spain) – the global no. three plasma specialist; c.18% market share – has had a tough ride since the COVID-19 outbreak. While the company ..."
Pages
60
Language
English
Published on
20/10/21
You may also be interested by these reports :
25/04/24
The Q1 results topped expectations, led by robust performances across all the key segments. While the management maintained its 2024 guidance, an ...
25/04/24
Q1 results surpassed expectations, on the back of a strong showing from immunology drug Dupixent, RSV vaccine Beyfortus and the new launches of ...
24/04/24
The Q1 sales met the street’s expectations, although forex, off-patent drugs’ generic/biosimilar erosion and declining COVID-19 sales adversely ...
24/04/24
Ipsen started 2024 on a positive note with sales ahead of the company-compiled consensus. Double-digit growth was led by Neuroscience, Oncology, and ...